Skip to main content

Table 2 Degree of protective efficacy of the vaccines as evaluated by the isolation rate of Brucella from the spleens of guinea pigs challenged with the virulent strain B. abortus 544

From: Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection

Vaccine

Route of administration

Log10CFU/spleen (mean ± SE)

Log10protection

*Value (P)

Monovalent Flu-NS1-124-Omp 16 (H5 + H1)

i.n.

2.0 ± 0.52

2.54

<0.01

c.

0.76 ± 0.44

3.78

<0.001

s.c.

1.26 ± 0.52

3.28

<0.005

Monovalent Flu-NS1-124-L7L12 (H5 + H1)

i.n.

1.22 ± 0.50

3.32

<0.001

c.

2.4 ± 0.25

2.14

<0.005

s.c.

1.46 ± 0.39

3.08

<0.001

Bivalent vaccine formulation Flu-NS1-124-Omp 16 + Flu-NS1-124-L7L12 (H5 + H1)

i.n.

1.28 ± 0.52

3.26

<0.005

c.

0.64 ± 0.40

3.90

<0.001

s.c.

1.68 ± 0.51

2.86

<0.005

B. abortus 19

s.c.

0.42 ± 0.26

4.12

<0.001

Control (PBS)

s.c.

4.54 ± 0.43

0.00

 
  1. i.n. – intranasally, c. – conjunctivally, s.c. – subcutaneously; *compared with control group. Statistical analysis was performed using a one way ANOVA followed by Tukey’s multiple comparisons test.